Vascular BioSciences Awarded $1.2 Million Contract from the NHLBI's VITA Program to Develop CAR Peptide Therapeutic Adjuvant for PAH Targeted Therapy


VBS announced the award of a $1.2 million, milestone-based, 3-year contract from the National Heart Lung Blood Institute (NHLBI) of the National Institutes of Health (NIH) to expedite the development of CAR therapeutic peptide pulmonary hypertension

Goleta (I-Newswire) January 28, 2014 - Vascular BioSciences (VBS) announced the award of a $1.2 million, milestone-based, 3-year contract from the National Heart Lung Blood Institute (NHLBI) of the National Institutes of Health (NIH) to expedite the development of CAR therapeutic peptide for pulmonary hypertension under NHLBI's Vascular Interventions/Innovations and Therapeutic Advances (VITA) program. This contract recognizes CAR's powerful ability to increase the benefits of PAH drugs by selectively targeting the pulmonary vasculature.

The overall objective of the VITA program is to enable and accelerate the development of promising diagnostic and therapeutic modalities for vascular diseases, thrombotic disorders, and pulmonary hypertension.

VBS was awarded the contract to speed up the development of "CAR Peptide Therapeutic Adjuvant for PAH Targeted Therapy" in collaboration with the scientific principal investigator, Dr. Masanobu Komatsu of the Sanford-Burnham Medical Research Institute at Lake Nona in Orlando, Florida.

Dr. Masanobu Komatsu commented, "I am very excited about the potential clinical utility of CAR as a therapeutic adjuvant for pulmonary hypertension. I am also very enthusiastic about our continuous collaboration with Vascular BioSciences and hope that we will together develop a novel intervention for this devastating lung disease."

CEO of Vascular BioSciences, David Mann added, "Our collaboration to develop targeting peptides as therapeutic adjuvants has resulted in the discovery of the remarkable ability of CAR peptide to selectively amplify the effects of co-administered compounds in a targeted manner. We look forward to harnessing this ability of CAR peptide to enable targeted treatment for pulmonary hypertension patients."

About Vascular BioSciences
Vascular BioSciences, a diversified biomedical company with operations in California and North Carolina, provides disease solutions in order to enhance and prolong human life

Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides molecular diagnostic services, and through its majority owned subsidiary VBS Pharmaceuticals, develops targeted therapeutics for patients with difficult‒to‒treat diseases.

More information about the CAR peptide and VBS is available at www.vascularbiosciences.com

For more information, please contact: dmann@vascularbiosciences.com






About Vascular Biosciences

Vascular BioSciences, a diversified biomedical company with operations in California and North Carol   More..ina, provides disease solutions in order to enhance and prolong human life.
Vascular BioSciences makes interventional catheters to obtain endoarterial biopsies, provides molecular diagnostic services, and advances therapies in order to improve disease outcomes for patients with significant unmet medical needs.Less..

Contact Information

Vascular Biosciences
David Mann
72 Santa Felicia Drive, Goleta, CA
Unit B
93117
Phone : 858-273-2744

Published in:

Medical > Pharmaceuticals

Published On:

January 28, 2014

Print Release:

Print Release

If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the I-Newswire.com press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.


Related Releases

Teeth Whitening Melbourne - Hollywood Smiles Now Available in Melbourne
Melbourne Dentist Clinic now offers Teeth Whitening Melbourne, which delivers brilliant sparking 'Hollywood' smiles under an hour.

Maintaining Accuracy Levels in Medical Coding Reports with the Help of Medical Coding Company:
With technologies are progressing day by day, most healthcare companies want to offshore their works to Medical Coding Company for lowering overhead expenses.

Dentist Sydney - Emergency Dentist in Sydney, Australia
Need an Emergency Dentist in Sydney? We can help! Dental emergencies are never convenient and often it is difficult to find a dentists in Sydney which has appointments available. This is why Sydney Dentist Clinic now offers Sydney Emergency Dentis

Meds India Offering Quality Medicines At Highly Reasonable Prices
Meds India, the India based premier online pharmacy has announced reduced prices on a range of already affordable medicines.

Wellbe Announces Webinar on Getting Started with Bundled Payments for Orthopedics
Speaker: Gabrielle White, RN, CASC, Executive Director at Hoag Orthopedic Institute